Age-related methylation may have the potential to behave as a mutator process. To clarify the physiological consequence of age-related methylation of tumor suppressor and tumor-related genes, we studied promoter methylation status in non-neoplastic cells of various organs obtained at autopsy by methylation-specific PCR. Promoter methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes, which are frequently silenced in certain human malignancies, was studied in non-neoplastic cells of the esophagus, stomach, small and large intestines, liver, pancreas, kidney and lung obtained from 38 Japanese autopsies. The tumor suppressor and tumor-related genes, except APC and RASSF1A, were generally unmethylated in samples obtained from people who were less than 32 years old (n ¼ 11). Methylated promoters were present at variable frequencies in a tissue-specific manner in samples obtained from people who were greater than 42 years old (n ¼ 27), although GSTP1 and hMLH1 methylation was absent or infrequent and lacked tissue specificity. In the majority of organs, the incidence of age-related methylation paralleled the reported methylation incidence in malignant counterparts. Thus, age-related methylation of a different set of genes is thought to constitute a field defect in different organs.
Introduction
In various types of human tumors and cells that are aging, CpG islands in promoters of genes important in tumor generation are methylated (Issa, 2000; Esteller et al., 2001; Jones and Laird, 1999) . Age-related methylation may have the potential to behave as a mutator process, resulting in the simultaneous silencing of multiple genes in aging tissue (Issa, 2000) , and exhibiting considerable tissue-specific differences (Ahuja et al., 1998; Issa, 2000) . The mechanism of age-related methylation is unknown; however, environmental and genetic factors may influence an individual's susceptibility (Issa, 2000; Paz et al., 2002) . In spite of the significance of age-related methylation, few reports focused on this phenomenon probably because of the lack of non-neoplastic tissue samples, except those from cancer-bearing organs. We have recently reported that methylation of E-cadherin, hMLH1 and p16 was present in neoplastic and non-neoplastic gastric epithelia at variable frequencies, and that the significance of detecting methylation in gastric epithelia differed among genes by comparing the methylation status in neoplastic and non-neoplastic gastric epithelia obtained from patients with and without gastric cancer (Waki et al., 2002) . In this study, we examined promoter methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes, which are frequently silenced by promoter hypermethylation in certain human malignancies, in non-neoplastic cells of various organs obtained at autopsy providing essential age-related methylation data of physiological consequences. In addition, we compared the results with reported incidences of malignant counterparts.
Results

Methylation in autopsy samples of younger individuals
Examples of the methylation-specific PCR (MSP) results (case No. 4) are shown in Figure 1 . The methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes in nonneoplastic tissue samples obtained from the younger age group (n ¼ 11) are listed in Table 1 (case Nos 1-11), and the methylation frequencies are demonstrated in Figure 2a . Methylation was generally rare in this group, except for APC and RASSF1A, which were methylated in several tissue samples, including those from 2-yearold male who died of myocarditis (case No. 4 in Table 1 ). The samples from a 14-year-old male who died of rhabdomyosarcoma (case No. 6 in Table 1 ) exhibited methylation in several genes.
Methylation in autopsy samples of elderly individuals
Examples of the MSP results (case No. 36) are shown in Figure 1 . The methylation status of APC, DAP-kinase, E-cadherin, GSTP1, hMLH1, p16, RASSF1A and RUNX3 genes in non-neoplastic tissue samples obtained from the elderly individuals (n ¼ 27) are listed in Table 1 (case Nos 12-38), and the methylation frequencies are demonstrated in Figure 2b . Methylation was present at variable frequencies in a tissue-specific manner. APC methylation preferentially occurred in the stomach, duodenum, liver, pancreas and lung; E-cadherin and DAPkinase in the stomach, small and large intestines; RASSF1A in the rectum, liver, pancreas and kidney; p16 and RUNX3 in the stomach. hMLH1 and GSTP1 methylation was infrequent or absent and lacked tissue specificity.
Discussion
In this study, we demonstrated the significant differences of susceptibility to age-related methylation among genes in different organs. Methylation of APC in the stomach, duodenum, liver, pancreas and lung, and that of RASSF1A in the colorectum, pancreas and kidney appeared earlier and became very frequent since around 40 years of age. Methylation of E-cadherin and DAPkinase was frequently present in the stomach, small and large intestines since around 40 years of age. p16 also became methylated less frequently since around 40 years of age, and was mostly restricted to the stomach. The exact age breakdown of these genes remained uncertain because of the lack of autopsies with age between 32 and 42 years. RUNX3 methylation preferentially occurred in the lower third portion of the stomach from very old individuals greater than 70 years of age. hMLH1 and GSTP1 methylation was infrequent or absent and lacked tissue specificity. Although environmental factors, such as tobacco-smoking (Yanagawa et al., 2002) and Helicobacter pylori infection (Chan et al., 2003) , as well as genetic factors (Paz et al., 2002) , might influence an individual's susceptibility to age-related methylation, it is apparent that detectable methylation of tumor suppressor and tumor-related genes accumulated in non-neoplastic tissues of elderly individuals in a tissue specific manner. Although the frequencies of the presence of methylated genes were almost constant after 40 years of age, the number of methylated cells and extent of methylated CpGs in each cell likely increases with age toward complete promoter hypermethylation, which leads to loss of gene function (Nakagawa et al., 2001) .
In the majority of the organs, the incidence of agerelated methylation was parallel with reported incidences of methylation in malignant counterparts. For example, the incidence of APC age-related methylation was high in the stomach, liver, pancreas and lung, while it was low in the colorectum and kidney. This was also true for their malignant counterparts (Tsuchiya et al., 2000; Virmani et al., 2001; Esteller et al., 2001; Usadel et al., 2002) . The DAP-kinase methylation frequently occurred in the non-neoplastic gastric epithelia in elderly individuals, as well as in gastric cancers Kang et al., 2001) , while it was rare in the nonneoplastic epithelia of the liver, pancreas and lung, as well as in their malignant counterparts (Ueki et al., 2000; Esteller et al., 2001; Zochbauer-Muller et al., 2001) . In contrast, we also found the absence or low frequency of age-related methylation despite the frequent occurrence in malignant counterparts, such as Ecadherin in the liver and kidney (Matsumura et al., 2001; Nojima et al., 2001) ; hMLH1 in the stomach and colorectum (Toyota et al., 1999a (Toyota et al., , 1999b Kang et al., 2001; Waki et al., 2002) ; p16 in the esophagus, colorectum, pancreas, kidney and lung (Toyota et al., 1999a (Toyota et al., , 1999b Ueki et al., 2000; Esteller et al., 2001; Zochbauer-Muller et al., 2001; Tokugawa et al., 2002) ; GSTP1 in the liver (Esteller et al., 2001) and RSASF1A in the stomach and lung (Byun et al., 2001; Tomizawa et al., 2002) . Such differences in methylation patterns may correspond to type A (aging-specific) and type C (cancer-specific) methylation previously described for gastric and colorectal cancers (Toyota et al., 1999a (Toyota et al., , 1999b . Toyota et al. (1999a) suggested that initially, type A methylation arises as a function of age in normal colorectal cells and by potentially affecting genes that regulate the growth and/or differentiation of these cells. Such methylation Figure 1 MSP of autopsy samples (a, 2-year-old male; b, 82-year-old male), a, APC; b, E-cadherin; c, DAP-kinase; d, RASSF1A, e, p16; f, RUNX3; g, hMLH1; h, GSTP1; i, unmethylated-sequence-specific PCR for E-cadherin. Methylated PCR products are present in lanes 1-3, 5, 11 and 12 (a-a) and lanes 1-3 (b-a) for APC, lanes 2, 3, 5-9 (b-b) for E-cadherin, lanes 1-3, 5-9 (b-c) for DAP-kinase, lanes 11 and 13 (a-d) and lanes 3, 8-11 and 13 (b-d) for RASSF1A, lanes 3 and 11 (b-f) for RUNX3, lanes 3 and 8 (b-g) for hMLH1. Unmethylated E-cadherin PCR products are present in all the samples (a-i and b-i). Lanes: 1, stomach (upper); 2, stomach (middle); 3, stomach (lower); 4, esophagus; 5, duodenum; 6, jejunum; 7, ileum; 8, colon; 9, rectum; 10, liver; 11, pancreas; 12, lung; 13, kidney; P, positive control; and SM, size marker Age-related methylation T Waki et al could account, in part, for the hyperproliferative state that is thought to precede tumor formation in the colon, and that type C methylation affects only a subset of tumors, which then evolve along a global hypermethylation pathway (Toyota et al., 1999a) . However, hMLH1 methylation, which was thought to be cancer-specific Age-related methylation T Waki et al (Toyota et al., 1999a) , was a common age-related event in normal colonic mucosa, when entire hMLH1 promoter B700-bp region was analysed (Nakagawa et al., 2001) . hMLH1 methylation is partial in normal colonic mucosa and increases with age, which spreads to reach a threshold, and ultimately shuts down protein expression (Nakagawa et al., 2001) . Therefore, these contradictory results might be due to analysis of different CpG sites in these studies (Nakagawa et al., 2001) . Moreover, affected cells distribute at multiple sites of the colon (Nakagawa et al., 2001) . If these are true for other tumor suppressor and tumor-related genes and if critical CpG sites for each gene silencing are more precisely analysed, age-related methylation may be cancer-specific. This hypothesis is supported by the observation that DAP-kinase methylation was present in virtually every tumor and normal gastric and colorectal sample when the edge of CpG island was examined, although it turned out as a more infrequent cancerspecific phenomenon after the central region of the CpG island was analysed (Satoh et al., 2002) . Alternatively, age-related methylation is not immediately oncogenic and gradually spreads to inactivate gene function. Therefore, the significance of methylated gene detection depends on the position of the examined CpG sites. It is possible that age-related methylation is prone to accumulate additional genetic and epigenetic alterations (Belinsky et al., 2002) . Specific circumstances may be required for these additional alterations because agerelated methylation of several genes was also present in the small intestine where tumor evolution is extremely rare.
As for clinical applications, the detection of cancerspecific methylation described above may be used as a diagnostic tool in a variety of sources including biopsy samples, sputum, gastric juice, bile, pancreatic juice and urine. We previously showed that hMLH1 methylation was present not only in neoplastic but also in nonneoplastic epithelia of cancer-bearing stomachs, although detection of hMLH1 methylation in nonneoplastic cells from nongastric cancer patients was rare (Waki et al., 2002) . Similarly, a strong association between p16 methylation in the bronchial epithelium and corresponding primary lung cancer has been observed (Belinsky et al., 2002) , while p16 methylation was exceptional in the non-neoplastic lung tissue samples from non-lung cancer patients demonstrated in this study. In such situations, methylated gene detection can be utilized as a precancerous signal.
Materials and methods
Samples
Non-neoplastic mucosal tissue samples were obtained from the upper, middle and lower portions of the stomach, as well as the esophagus, duodenum, jejunum, ileum, colon, rectum, liver, pancreas, lung and kidney at autopsies. Note that some tissue samples were not available. The subjects consisted of 24 males and 14 females, ranging in age from 0.7 to 87 years (average 54.4 years excluding two stillborn infants). There were 24 malignant disease cases, and non-neoplastic tissue samples from organs in which a tumor evolved or invaded were excluded. A total of 381 non-neoplastic tissue samples were ultimately studied. Owing to the lack of autopsies with age between 32 and 42 years and incidence of carcinoma generally rises up after 40 years of age, the autopsies were divided into two age groups for comparison: younger (11 patients less than 32 years old; range, 0.7-31 years; average 14.0 years excluding stillborn infants) and elderly (27 patients greater than 42 years old; range, 43-87 years; average, 67.9 years). All samples were snap frozen and stored at À801C until processed. Genomic DNA was extracted with standard procedures.
Bisulfite modification and MSP
DNA samples were treated with bisulfite to convert all unmethylated cytosines to uracils, while leaving methylated cytosines unaffected. Briefly, 2 mg of genomic DNA was denatured by NaOH treatment and modified by sodium bisulfite. The samples were then purified using the Wizard DNA purification resin (Promega, Madison, WI, USA), treated with NaOH, recovered in ethanol and resuspended in 30 ml of distilled water. Amplification was performed in a 20 ml volume containing 2 ml GeneAmp PCR Gold Buffer (PE Applied Biosystems, Foster City, CA, USA), 1.0 mm MgCl 2 , 1 ml of each primer, 0.2 mm dNTPs, and 1 U Taq polymerase (AmpliTaq Gold DNA Polymerase, PE Applied Biosystems). Hot start PCR was performed in a thermal cycler (GeneAmp 2400, PE Applied Biosystems) for 35 cycles, which consisted of 951C for 15 s, 551C for 15 s and 721C for 30 s, followed by a final 7 min extension at 721C. A positive control and negative control (distilled water without DNA) were included for each amplification.
The PCR products were separated on a 6% nondenaturing polyacrylamide gel. MSP primer sequences were TGT TTT GCG GAT TTT TTT and GCA ATA AAA CAC AAA CCC CG for APC (158 bp); GGA TAG TCG GAT CGA GTT AAC GTC and CCC TCC CAA ACG CCC G for DAP-kinase (98 bp); GGT GAA TTT TTA GTT AAT TAG CGG TAC and CAT AAC TAA CCG AAA ACG CCG for E-cadherin (204 bp); TTC GGG GTG TGC GGT CGT C and GCC CCA ATA CTA AAT CAC GAC G for GSTP1 (91 bp); ACG TAG ACG TTT TAT TAG GGT CGC and CCT CAT CGT AAC TAC CCG CG for hMLH1 (115 bp); GGG TCG GAG GGG GTT TTT TC and CAA CCG CCG AAC GCA CTC GA for p16 (97 bp); GTG TTA ACG CGT TGC GTA TC and AAC CCC GCG AAC TAA AAA CGA for RASSF1A (93 bp); ATA ATA GCG GTC GTT AGG GCG TCG and GCT TCT ACT TTT CCC GCT TCT CGC G for RNNX3 (117 bp). All DNA samples were checked for bisulfite modification using the unmethylated E-cadherin primer set: GGT AGG GTG AAT TTT TAG TTA ATT AGT GGT A and ACC CAT AAC TAA ACC AAA AAC ACC A (211 bp). Sss-I methylase (New England BioLabs, Inc., Beverly, MA, USA) was used to methylate 100 mg of peripheral blood DNA and was modified by sodium bisulfite as described above.
